The effect of temozolomide (TMZ) and radiotherapy (RT) in the treatment of glioblastoma multiforme (GBM) has been well documented in randomized controlled trials. Here we present our findings on the effect of TMZ added to RT at a population level. The Cancer Registry of Norway was searched for patients with a GBM diagnosis from January 1, 2000 to December 31, 2007. Subsequently, the prescriptions registered to these patients were obtained from the Norwegian Prescription Database. The data were analyzed according to era (pre-TMZ introduction or post-TMZ introduction) and according to treatment received. Furthermore, a matching procedure was utilized to reduce the bias between the RT 1 TMZ and RT alone treatments so that the effect of TMZ could be better scrutinized. We identified 1157 GBM patients. The median overall survival (OS), in months, was 8.3 (95% confidence interval: 7.6 -9.0) and 10.1 (95% confidence interval: 9.1 -11.0) in the pre-TMZ and TMZ eras, respectively (P < .001). By treatment, we found median OS for the control, RT alone, and RT 1 TMZ groups to be 2.5, 9.0, and 16.2 months, respectively (P < .001). Two-year survival was 0%, 4%, and 25%, respectively. The effect of age on TMZ effect was insignificant. In the matched group analysis, TMZ provided a 7.6-month OS benefit. Our population data reproduce the beneficial effect of TMZ from randomized controlled trials with a median OS of 16.2 months and 25% 2-year survival.
G lioblastoma multiforme (GBM) is the most common primary brain tumor and also has the poorest outcome, with median overall survival (OS) often ,1 year. 1, 2 It is well documented that both gross total resection (GTR) of tumor and radiotherapy (RT) prolong OS for these patients. 3 -5 Before 2005, the documented effects of chemotherapy were only marginal, hence primary treatment in most cases was surgery followed by RT alone. 6 In 2005, Stupp et al 7 showed in a randomized controlled trial (RCT) that temozolomide (TMZ; Temodar) given concomitant with RT followed by adjuvant TMZ was beneficial for GBM patients and that median OS could be prolonged to 14.6 months, up from 12.1 months in the group receiving RT alone. Furthermore, 20% of the patients receiving TMZ + RT survived .2 years.
However, it has been reported that patients in RCTs have better outcomes than can be expected in population settings, where exclusion criteria do not exist and where follow-up might be less rigorous than in an RCT. 2, 8 As Norway has a unique opportunity for investigating effects on the health of the population due to several prospectively maintained national databases that can be linked, we can report the effect of the introduction of TMZ on the survival of GBM patients at a population level from 2 prospectively maintained national databases: the Cancer Registry of Norway (CRN) and the Norwegian Prescription Database (NPD).
Materials and Methods
Norway has a well-defined population of 4.9 million people, each of whom has a unique identification number, allowing for follow-up at the population level. In this study, we linked the CRN 9 and the NPD 10 to gain information on patients with GBM and their TMZ prescriptions.
The CRN, founded in 1951, maintains a prospective database on all neoplasms diagnosed in Norway. It encompasses both malignant and benign tumors of the CNS. Reporting to the registry is compulsory by law, and the registry is based on clinicians' reports, subsequent pathology reports, and information from death certificates reporting neoplastic disease. The quality of the registry is maintained by ensuring that missing reports from attending clinicians or pathologists are requested by direct contact. In case of multiple operations on the same patient with multiple histologic specimens, the database is updated accordingly. Histologies of the neoplasms in our time period (2000 -2007) are coded according to the International Classification of Diseases for Oncology, second revision. Data from the CRN have undergone quality control and are valid for population studies. 11, 12 The registry also retrieves data electronically, ensuring complete information on the radiation dose and fractions prescribed in all patients. Furthermore, the unique identification number of each individual is maintained by the government. Change to death status is conveyed to the CRN.
The NPD was founded in 2004 by the Norwegian Institute of Public Health, and this database is for all prescriptions dispensed to patients from all Norwegian pharmacies. The collection of this information is regulated by Norwegian law. The NPD includes information about individual patients and their different prescriptions (type of drug, strength of drug, package size, and when dispensed). The NPD contains multiple records per patient because each patient can have multiple prescriptions registered.
The recommended primary treatment of GBM in Norway changed during the time period 2000 -2007, from GTR followed by RT to GTR followed by RT with concomitant and adjuvant TMZ. The change largely took place in 2004. Neuro-oncologic treatment typically starts within 6 weeks after the operation. RT + TMZ is usually administered in an outpatient setting, and all prescription data are automatically registered in the NPD. RT is now given mainly over 6 weeks to a total dose of 60 Gy in 2-Gy fractions. Prior to 2004 the RT dose prescribed was mainly 54 Gy over 6 weeks in 1.8-Gy fractions, with some patients being given 48 Gy in fractions of 1.6 Gy twice a day.
We searched the CRN for all records with a diagnosis of GBM from Januaruy 1, 2000 to January 1, 2007, resulting in 1345 records. Four of these patients were lost to follow-up due to emigration and were censored at the time of emigration. Also excluded were 155 patients in whom the GBM diagnosis was based solely on imaging or autopsy. The last date of follow-up was December 15, 2009 .
The NPD data were converted into wide form with one record per patient, and we generated new columns for the first and last date of prescriptions. Subsequently, the NPD and CRN databases were merged on the unique patient ID. There were 28 patients registered with a GBM diagnosis who postoperatively received TMZ but not RT, and there was 1 patient registered without a valid birthdate. These patients were excluded. The data set thus comprised a total of 1157 unique GBM patients.
The data were divided into groups based on the timing of chemotherapy. We dichotomized this into concomitant TMZ with or without adjuvant TMZ and adjuvant TMZ alone. "Concomitant TMZ" was defined as treatment of patients having their first TMZ prescription ≤60 days after their first RT dose. "Adjuvant TMZ" was defined as treatment of patients having their first TMZ prescription .60 days after their first RT dose. For the purpose of comparing our data with the Stupp data, 7 we extracted a group comprising patients with GBM in the age group 18-70. We also divided the patients into groups based on the time of diagnosis, ie, whether TMZ was introduced or not (pre-TMZ or TMZ era).
Ethics
The study was approved by the data protection officers of the CRN and the NPD.
Statistics
Data were summarized as medians and interquartile ranges. Survival curves were generated using the Kaplan -Meier estimator. To decrease the inherent bias in nonrandomized data, a matching procedure was performed by utilizing coarsened exact matching (CEM). 13 We matched RT alone and TMZ + RT groups by sex, radiation dose, age, and time until RT. To validate the performance of the matching procedure, we present the standardized differences as means between the RT alone and the TMZ + RT groups for the covariates including interactions and squared terms, thus better describing the distributions in the 2 groups.
Since all matching estimators depend on the assumption that there are no unobserved confounders accounting for the selection process into treatment or control group, a sensitivity analysis was performed. This analysis was done using the rbounds package, which in turn is based on the methodology detailed by Rosenbaum to demonstrate the impact necessary for any unmeasured confounder to invalidate the findings of the matched analysis.
14, 15 Adjusted analyses using Cox regression were done after verification of the proportional hazard assumption. Buckley-James regression allowed the fitting of linear models to right-censored data. Here we used a normal distribution link to estimate the survival benefit in months for the right-censored data. 16 Only 5% of the matched data set were censored. Furthermore, we present bootstrapped confidence intervals (CIs; 200 resamples with replacement from the original data set) for the coefficients in the Buckley-James regression to mitigate the uncertain properties of the Buckley-James covariance estimator.
Linearity of covariates was checked using restricted cubic spline (RCS) modeling and compared with models without RCS. Interactions were checked with the same methodology. P , .05 was considered statistically significant. R version 2.13.0 was used for all statistical analyses.
Results
A total of 1157 patients with GBM diagnosed between January 1, 2000 and December 31, 2007 were included in this study. First we divided the GBM population into a group diagnosed before the introduction of TMZ and a group diagnosed after the introduction of TMZ (Table 1) ; median OS, in months, was 8.3 (95% CI: 7.6 -9.0) and 10.1 (95% CI: 9.1 -11.0), respectively (P , .001) (Fig. 1A) . In the subset of patients receiving RT alone, median OS was 10.1 months (95% CI: 9.4 -11.03) in the pre-TMZ era and 6.9 months (95% CI: 6.1 -8.0) in the TMZ era (P , .001) (Fig. 1B) . Finally, we analyzed the subset of patients who did not receive any oncologic treatment. Median OS was 2.8 months (95% CI: 2.5 -3.2) in the pre-TMZ era and 2.1 months (95% CI: 1.6 -2.8) in the TMZ era (P ¼ .08) (Fig. 1C) .
Next, we divided the GBM population into the following 3 groups based on treatment received: RT + TMZ, RT alone, and control (no TMZ or RT). There was a significant trend toward more advanced treatment being offered to men and to younger people. Furthermore, patients being offered TMZ received a higher RT dose.
Median OS for the control, RT alone, and RT + TMZ groups was 2.5, 9.0, and 16.2 months, respectively (log-rank test, P , .001) for the entire population. Patients surviving 2 years were 0%, 4%, and 25%, respectively. In the 18 -70 age group, median OS was 2.3, 9.8, and 16.3 months, respectively (Table 2 ). In patients .70 years old, we found median OS to be 2.8, 7.4, and 13.4 months in the respective groups.
Kaplan -Meier plots demonstrate these findings ( Fig. 2A-2C) (P , .001) . Furthermore, we dichotomized the RT + TMZ group into a group receiving TMZ both concomitantly and as an adjuvant (first TMZ prescription ≤60 days after RT) and a group receiving TMZ as only an adjuvant (first TMZ prescription .60 days after RT). The difference in OS between The entire GBM population stratified by era, demonstrating increased OS after TMZ was introduced (P , .001). (B) We excluded the patients who received TMZ and saw that the OS was reduced in the post-TMZ era (P , .001). (C) We analyzed the subset not receiving radiotherapy or TMZ and demonstrated that the OS for this population is similar (P ¼ .08).
these 2 groups was not statistically significant (log-rank test, P ¼ .18) (see Supplemental material Fig. 3 ). We subsequently matched the RT alone (n ¼ 356) and the RT + TMZ groups (n ¼ 338) using CEM, resulting in a similar distribution of covariates. Neither the covariates nor their interactions and squared terms revealed a standardized difference of more than 0.21 between the 2 groups (see Supplemental Fig. 4) .
Next we performed adjusted Buckley-James and Cox regression analyses on the matched samples, demonstrating that age, RT dose, and TMZ introduction are highly associated with longer OS after the diagnosis of GBM (Table 3) . Using the Buckley-James method, we estimated that TMZ increases survival on average 7.6 months (95% CI: 5.7 -9.5; P , .001).
The interactions between age and TMZ treatment and age and RT dose were statistically insignificant (P ¼ .12 and P ¼ .67, respectively). A sensitivity analysis was done, demonstrating that the findings in the matched group analysis were reasonably robust to unobserved confounders, in that any unobserved confounder would need an odds ratio of 4 to invalidate the findings.
Discussion
In this nationwide analysis of survival in all GBM patients, we found median OS, in months, to be 8.3 (95% CI: 7.6 -9.0) and 10.1 (95% CI: 9.1 -11.0) before and after, respectively, the introduction of TMZ. Thus, we largely confirm the results of RCTs on the effect of TMZ on the survival of GBM patients at a population level.
For the patients who did not receive adjuvant oncologic treatment, median OS was statistically insignificant after TMZ was introduced (2.8 vs 2.1 months, P ¼ .08). However, the patients who received RT demonstrated a significantly better median OS before the introduction of TMZ (10.1 vs 6.9 months, P , .001). This is most likely explained by a reverse selection bias, in that patients with good performance scores received TMZ treatment, thus depriving the RT + TMZ group of a better prognosis in the TMZ era. Another large study from Italy with 1059 patients demonstrated a median OS of 9.5 months after the introduction of TMZ. 18 This is similar to our numbers, and the authors also found that approximately 25% of the GBM patients survived more than 2 years.
When we stratify the entire GBM population on treatment, we find survival rates of 16.2, 9.0, and 2.5 months in the RT + TMZ, RT alone, and control groups, respectively. The 16.2-month median OS is comparable to the median OS of 14.6 months presented by Stupp et al in the original RCT. 7 The difference in survival between our study and the Stupp study can most likely be attributed to the different zero points for survival. We used time of diagnosis, while Stupp et al used time of randomization, in practice ,7 days before start of RT (personal communication, Roger Stupp). The median time to start of RT in our study was 42 days, resulting in median survival in the RT + TMZ group calculated, according to Stupp, of 14.8 months, thus The effect of TMZ on GBM survival in a well-defined population lending further support to the notion that TMZ is beneficial at a population level. Several recent studies indicate that elderly GBM patients receive suboptimal treatment. 2, 19, 20 We found insignificant differences between the entire population and the group comprising the 18 -70 age group subpopulation with regard to survival, irrespective of adjuvant therapy. The isolated analysis of patients aged .70 years also demonstrates a clear beneficial effect of TMZ on OS, although the number of patients (n ¼ 22) is limited and the CI is large. Furthermore, interactions between age and TMZ effect on survival in the model were insignificant. Our data thus do not rule out an effect of TMZ in elderly patients as well. However, this must be verified in a prospective randomized trial. 19,21 -24 Median OS in the RT alone group was 9.0 months measured from time of diagnosis, but only 7.4 months when measured from start of RT, as median time until start of RT was 48 days. This compares unfavorably with the findings of Stupp et al, where median time of survival in the RT group was 12.1 months. 7 This difference can probably be explained to a large extent by the nonrandomized nature of this study. After TMZ was introduced, patients with good performance would receive TMZ + RT, while patients with poorer performance would receive RT alone. This is in contrast to the findings of Stupp et al, where the RT + TMZ and RT alone groups were randomized and thus comprised patients with the same performance status. Another factor that could explain this difference is the lower total RT dose given before the later standard of 60 Gy. The results from the adjusted Buckley-James regression indicate that each extra Gy prescribed to the patient entails a 0.2-month survival benefit (95% CI: 0.13 -0.28; P , .001) and that the effect is linear. Thus the discrepancy in survival in the RT alone group between the 2 studies can be explained by a difference both in performance status and in RT dose prescribed. There is a significant effect of TMZ + RT vs RT alone in both (A), (B), and (C) (P , .001). Furthermore, there is a significant effect of RT vs no adjuvant therapy (P , .001). 
Limitations
The main limitation of the study is the retrospective nature of the analysis from 2 different prospectively maintained registers. The main assumptions in this study that we cannot verify are whether patients actually ingested the prescribed TMZ and whether some of the patients received TMZ as in-patients only, thus not being registered in the NPD. (The NPD does not maintain records of drugs dispensed to patients while admitted to the hospital.) However, in the latter case, this would most likely introduce a bias in disfavor of TMZ. The number of TMZ cycles was difficult to ascertain from the data file, and we have dichotomized this variable into yes/no. Another limitation is the degree to which TMZ has been used as salvage therapy for GBM patients diagnosed before TMZ was introduced as standard therapy. These patients already demonstrated long survival. This could produce a bias in favor of TMZ. We did separate analyses for patients according to whether TMZ prescriptions were registered within 60 days of RT or not. Our analyses did not show any significant differences between these 2 groups, and we thus believe that bias secondary to TMZ as salvage therapy is unlikely. Furthermore, we know that some of the patients received nitrosourea, but more specific information on this was not available to us. Another limitation is the selection bias that we tried to overcome by using matching methods to ensure reasonably similar groups for the analyses, which have been further adjusted by standard multivariate regression methods, as advocated in the literature. 25 There are other important prognostic factors with regard to survival that are not registered, ie, unmeasured confounders. Gorlia et al 26 demonstrated the following factors as important in predicting OS: O 6 -methylguanine-DNA methyltransferase (MGMT) promoter methylation status, age, performance status, extent of resection, and Mini-Mental State Examination. However, none of these factors had a hazard ratio over 4. In their 5-year follow-up of the TMZ data, Stupp et al demonstrate that neither Recursive Partitioning Analysis class nor MGMT methylation have hazard ratios of such magnitude. 27 In a study by Stummer et al, 3 GTR confirmed on postoperative MRI entails a survival benefit of approximately 5 months (GTR 17.9 months vs subtotal resection 12.9 months). In the multivariate analysis, this translated into a hazard ratio of 3.4. However, the Stummer study did not include TMZ as adjuvant therapy. 3 In a small German study with 66 patients, a significant association was found between OS and patients with MGMT promoter methylation status and extent of resection with hazard ratios of 7.9 and 4.5, respectively. In a previous study from Oslo, the hazard ratio of resection vs biopsy was 2.72. 2 In this study, we provide a sensitivity analysis showing that any confounder not controlled for would need an odds ratio of at least 4 to invalidate the findings presented here. Hence, we believe our findings are robust to the well-known prognostic factors in GBM.
Strengths
The major strengths of the study are the number of patients and the fact that the results are derived in a population setting outside an RCT. This generalizes the applicability of the results. Furthermore, the data from both CRN and NPD are prospectively entered, while the unique personal ID allows close surveillance with regard to patient status.
Conclusion
In a nationwide setting, we demonstrate that TMZ added to RT prolongs survival for GBM patients to 16.2 months from time of diagnosis and that 2-year survival is 25%.
